Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the September 19. 2013 edition of the journal Cell Reports, a team of researchers based at The Wistar Institute in Philadelphia, PA (USA), report on the mechanics by which melanoma can evolve resistance to a powerful combination of drugs — BRAF and MEK…Continue
Added by Peter Hofland, PhD on September 19, 2013 at 4:30pm — No Comments
Cells can promote tumor suppression via a process of irreversible arrest of proliferation called senescence. This process is thought to be associated with normal aging, but is also a protective measure against run-away cell replication. Studying the basic science of senescence gives biomedical researchers a better understanding of the mechanisms behind age-related diseases such as cancer.
Scientists from the…Continue
Added by Editorial Team on August 30, 2013 at 4:00pm — No Comments
Scientists at St. Jude Children’s Research Hospital in Memphis, Tennessee (USA), have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to develop a two-drug combination therapy that offers a more effective method of killing tumor cells. In doing so, they have give new hope to children and adults with the disease. The findings appear in the August 29, 2013 online edition of the journal…Continue
Added by Editorial Team on August 29, 2013 at 10:30am — No Comments
Scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine may soon succeed in diagnosing and treating pancreatic cancer, one of the most lethal and hard-to-treat types of cancer.
The investigators report in the an article published in the July 16 online edition EMBO Molecular Medicine that they have identified a new molecular…Continue
Added by Editorial Team on August 22, 2013 at 8:30pm — No Comments
Scientists involved in basic research as well as clinicians have a keen interest in understanding how the cells of our body move. Cells must be mobile in order for organisms to grow, to heal, to transmit information internally, to mount immune responses and to conduct a host of other activities necessary for survival. But if cell mobility is unregulated, tumors can grow and spread or metastasize from the primary tumor to secondary locations throughout the body.
Added by Editorial Team on August 12, 2013 at 5:00pm — No Comments
Scientists at The Scripps Research Institute (TSRI), a private, non-profit research organization engaged in basic biomedical science in La Jolla, California (USA), have discovered a new type of chemical modification that affects numerous proteins within mammalian cells. The modification appears to work as a regulator of important cellular processes including the metabolism of glucose. Further study of this modification could…Continue
Added by Editorial Team on August 1, 2013 at 8:00pm — No Comments
Health experts are urging government regulators to take action to protect the nation's youth by restricting the use of artificial tanning devices, which are linked to an increase in the risk of skin cancer, according to an article published online in the March 18, 2013 edition of Pediatrics, the journal of the American Academy of Pediatrics.
Indoor tanning has grown rapidly over the years with…Continue
Added by Peter Hofland, PhD on March 18, 2013 at 8:00am — No Comments
A new drug combination including an EGFR and COX-2 Inhibitors shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal of the American Association for Cancer…Continue
Added by Peter Hofland, PhD on February 19, 2013 at 8:00pm — No Comments
New research examining the role of race and ethnicity in an individual’s decision to become a donor for hematopoietic cell transplantation (HCT) identifies several factors associated with varied participation rates in national donor registries across racial/ethnic groups. Results of this first-of-its-kind study are published online today in Blood, the Journal of the American Society of Hematology (ASH).
Added by Editorial Team on December 20, 2012 at 10:00pm — No Comments
A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells (CTC) that carry cancer around the body through the bloodstream (illustration). Engineering and medical researchers at the …Continue
Added by Editorial Team on December 12, 2012 at 6:30pm — No Comments
Results from a completed Phase II study with the investigational FLT3 inhibitor, quizartinib (AC220; Astellas Pharma/Ambit Biosciences) as an oral monotherapy treatment regimen in patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) were presented earlier today at the 54th Annual Meeting of the American Society of Hematology (ASH).
The Phase II ACE study recruited patients into two separate cohorts of…Continue
Added by Editorial Team on December 10, 2012 at 4:30pm — No Comments
New pre-clinical data for RNAi therapeutics for the treatment of hemoglobinopathies, presented at the 54th American Society of Hematology (ASH) Annual Meeting being held December 8-11, 2012 in Atlanta, shows that ALN-TMP, an RNAi therapeutic targeting therapeutic targeting transmembrane protease serine 6 or Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model…Continue
Added by Peter Hofland, PhD on December 8, 2012 at 2:30pm — No Comments
The European Commission (EC) has approved bevacizumab (Avastin, Genentech/Roche)in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.
Bevacizumab is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. The additional approval of the medicine is important for women with ovarian cancer who are now able to…Continue
Added by Peter Hofland, PhD on October 31, 2012 at 1:00am — No Comments
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012). Renal cell carcinoma, also called kidney cancer or renal adenocarcinoma, is a type of kidney cancer that starts in the lining of the tubules in the kidney.
Prof Maria De Santis from Kaiser Franz Josef-Spital, Vienna, Chair of the ESMO 2012…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 8:00pm — No Comments
A new educational approach helps children with sickle cell disease complete MRI tests without sedation. Sitting still is tough for young children, making MRI scans a challenge. The scans require that patients remain motionless for extended periods. Findings from St. Jude Children's Research Hospital showed that a brief, targeted intervention dramatically increases the likelihood that children as young as 5 years old will be able to undergo testing without sedation.
Added by Peter Hofland, PhD on August 31, 2012 at 8:30am — No Comments
Reovirus (Reolysin®; Oncolytics Biotech, Calgary, AB, Canada), a proprietary variant of the Respiratory Enteric Orphan Virus, is a benign, double-stranded RNA human virus with oncolytic properties. In a variety of clinical trials, the virus has shown to selectively kill tumor cells with activated signaling through the RAS pathway.
The RAS protein family members belong to a class of protein called…Continue
Added by Peter Hofland, PhD on August 16, 2012 at 5:30am — No Comments
Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…Continue
Added by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments
Research published in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning. Scientists in the multi-institutional study – posted online by the journal on June 24, 2012 – say their findings open the potential for new treatments against radiation toxicity during cancer treatment or environmental…Continue
Added by Peter Hofland, PhD on June 24, 2012 at 10:00am — No Comments
BPM 31510 targets the metabolic machinery of the cancer microenvironment to reverse the aerobic glycolytic phenotype of cancer cells also called the Warburg phenotype. The Warburg phenotype has been related to the pathogenesis of schizophrenia, malignancy, metabolic syndrome x, autoimmune disease and neuronal degeneration.
The endogenous small molecule resident in mitochondria restores oxidative phosphorylation and confers re-capitulation of the BCL-2…
Added by Peter Hofland, PhD on June 12, 2012 at 5:00am — No Comments
A Phase III multicenter clinical trial finds that treatment with the investigational BRAF-targeted drug dabrafenib, an investigational, orally bioavailable inhibitor of the BRAF protein, reduced the risk of disease progression by 70% compared to standard…Continue
Added by Peter Hofland, PhD on June 5, 2012 at 6:30pm — No Comments